Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686561 | 1.00 | PIK3CA (0.45) | PIK3CAPIK3R1SMN1; SMN2MTORKDM4E | |
| SCHEMBL15765687 | 0.88 | PRKCI (0.38) | PIK3CAPIK3R1SMN1; SMN2 | |
| SCHEMBL30583830 | 0.86 | KDM4E (0.41) | PIK3CAPIK3R1KDM4EMEN1LMNA | |
| SCHEMBL26252977 | 0.86 | KDM4E (0.41) | PIK3CAPIK3R1KDM4EMEN1LMNA | |
| SCHEMBL1861694 | 0.85 | PIK3CA (0.53) | PIK3CAPIK3R1SMN1; SMN2MTORPIK3CD | |
| SCHEMBL1284930 | 0.84 | PIK3CA (0.52) | PIK3CAPIK3R1SMN1; SMN2MTORPIK3CD | |
| SCHEMBL1860315 | 0.84 | PIK3CA (0.45) | PIK3CAPIK3R1SMN1; SMN2MTORMAPT | |
| SCHEMBL1863634 | 0.82 | PIK3CA (0.47) | PIK3CAPIK3R1SMN1; SMN2MTORLMNA | |
| SCHEMBL1858759 | 0.82 | PIK3CA (0.47) | PIK3CAPIK3R1SMN1; SMN2MTOR | |
| SCHEMBL1859005 | 0.82 | SMN1; SMN2 (0.47) | PIK3CAPIK3R1SMN1; SMN2MTORMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | PIK3CA 58/4885PIK3R1 106/4885SMN1; SMN2 4192/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885PIK3R1 106/4885SMN1; SMN2 4184/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885PIK3R1 106/4885SMN1; SMN2 4184/4885 |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885PIK3R1 106/4885SMN1; SMN2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.